National Cancer Action Center

Tomorrow, the House Appropriations Committee is scheduled to consider the draft FY26 appropriations bill approved on September 2 nd by the House Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies. The bill includes an increase in funding for cancer research and cancer prevention and control programs.

More than 100 organizations representing millions of patients with serious health conditions and health care professionals sent a letter to Congress expressing their strong support for the Clinical Trial Modernization Act. Introduced in the House of Representatives in May 2025 by Reps. Raul Ruiz (D-CA) and August Pfluger (R-FL), the bipartisan legislation would help remove cost and geographic barriers to patient participation in clinical trials.

A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.

Today, the U.S. Senate Committee on Appropriations considered and approved its draft FY26 appropriations bill that includes increases for the National Institutes of Health (NIH) and increases for federal cancer research funding at the National Cancer Institute (NCI).